Form 4: Rocket Pharma Officer Sells Shares

Rocket Pharmaceuticals' Chief Science Officer, Jonathan David Schwartz, sold 2,545 shares of company stock.

Summary

• Jonathan David Schwartz, Chief Science & Gene Therapy Officer at ROCKET PHARMACEUTICALS, INC. (RCKT), reported a transaction.
• On November 18, 2025, Schwartz disposed of 2,545 shares of common stock.
• The shares were sold at a price of $2.983 per share.
• Following this transaction, Schwartz beneficially owns 299,064 shares of common stock.
• The holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.
• The transaction was not indicated as being made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 3

Explanation: A discretionary sale by a high-ranking officer, not part of a pre-arranged plan, can be interpreted as a negative signal regarding the insider's confidence in the company's near-term prospects.

Negatives

• Jonathan David Schwartz, Chief Science & Gene Therapy Officer, executed a discretionary sale of 2,545 shares of common stock, which was not indicated as part of a Rule 10b5-1 trading plan. Discretionary insider sales can sometimes be perceived as a negative signal by the market.

Related Party Transactions

• Jonathan David Schwartz, Chief Science & Gene Therapy Officer, sold 2,545 shares of common stock for $2.983 per share on November 18, 2025.

Stakeholder Impact

• Shareholders may perceive the discretionary insider sale as a potential signal of reduced confidence by a key executive, potentially impacting investor sentiment.

Key Dates

Recommendation

The filing reports a discretionary insider sale of common stock by a key officer, Jonathan David Schwartz, who is the Chief Science & Gene Therapy Officer. The transaction is not indicated as being part of a pre-arranged Rule 10b5-1 trading plan. Discretionary insider sales, especially by high-ranking executives, can sometimes signal a lack of confidence in the company's near-term prospects or valuation. However, the number of shares sold (2,545) represents a small fraction of his total beneficial ownership (299,064 shares). Investors should view this as a cautionary signal and consider it alongside other fundamental analysis before making investment decisions. A 'hold' recommendation is appropriate, advising investors to monitor future developments and broader company performance.

Keywords

ROCKET PHARMACEUTICALS, RCKT, insider trading, Form 4, stock sale, Jonathan David Schwartz, Chief Science & Gene Therapy Officer